Physician profile
Ryan Keith Brashear
NPI 1841309754
$8,315.20
in general payments reported to CMS, 2019-2025
36 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $722 · 2021: $1,496 · 2022: $1,462 · 2023: $954 · 2024: $1,226 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.42 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,137.69 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $965.52 | 2019-2025 | |
| Janssen Biotech, INC. | $703.24 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $479.84 | 2019-2024 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $470.45 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $467.90 | 2021-2025 | Opzelura |
| Amgen INC. | $446.08 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $324.04 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $286.26 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $275.15 | 2019-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.27 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Pfizer INC. | $216.71 | 2019-2025 | |
| Genzyme Corporation | $208.71 | 2019-2025 | |
| Galderma Laboratories, L.P. | $197.49 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $116.05 | 2022-2024 | Vtama |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $109.36 | 2021-2025 | Anzupgo, Adbry |
| Celgene Corporation | $86.61 | 2019 | |
| Mayne Pharma Commercial LLC | $86.59 | 2022-2025 | |
| Almirall LLC | $70.70 | 2020-2025 | Seysara, Klisyri |
| Medtronic, INC. | $47.38 | 2022 | |
| Paratek Pharmaceuticals, INC. | $46.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.95 | 2024 | Spevigo |
| Nabriva Therapeutics, Plc | $40.34 | 2021-2022 | |
| Genentech USA, INC. | $38.67 | 2019-2021 | |
| Biofrontera INC. | $37.79 | 2022 | |
| Integra Lifesciences Corporation | $28.63 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Octapharma USA, INC. | $24.10 | 2025 | Octagam Immune Globulin (Human) |
| Organon LLC | $19.55 | 2025 | Vtama |
| Botanix Sb INC | $17.85 | 2025 | Sofdra |
| Journey Medical Corporation | $15.62 | 2025 | |
| Epi Health, LLC | $14.43 | 2022 | |
| Medline Industries Lp | $14.22 | 2021 | |
| Arcutis Biotherapeutics, INC. | $13.58 | 2024 | Zoryve |
| Prugen, INC. Pharmaceuticals | $13.41 | 2019 | |
| Encore Dermatology INC. | $12.20 | 2019 | |
| Vyne Pharmaceuticals INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brashear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.